Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: An open-label trial

Arthritis and Rheumatism

Volumn 52, Issue 8, 2005, Pages 2478-2484

  Tugal Tutkun, Ilknur ^a   Mudun, Abdulbaki ^b   Urgancioglu, Meri ^a   Kamali, Sevil ^a   Kasapoglu, Esen ^a   Inanc, Murat ^a   Gül, Ahmet ^a,c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b OKMEYDANI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; PREDNISOLONE;

ADULT; ARTICLE; BEHCET DISEASE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTACT DERMATITIS; DRUG EFFICACY; DRUG INDUCED HEADACHE; ECZEMA; FOLLOW UP; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; INGUINAL HERNIA; INJECTION SITE REACTION; KIDNEY COLIC; LOW BACK PAIN; MALE; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; RASH; REMISSION; RESPIRATORY TRACT INFECTION; SCORING SYSTEM; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; BEHCET SYNDROME; CYCLOSPORINE; DRUG RESISTANCE, MULTIPLE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETREATMENT; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 23644447065     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21231     Document Type: Article

References (24)

1. Tugal-Tutkun I, Onal S, Allan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 2004;138:373-80.
2. Kaklamani VG, Kaklamanis PG. Treatment of Behçet's disease: an update. Semin Arthritis Rheum 2001;30:299-312.
3. Okada AA. Drug therapy in Behçet's disease. Ocul Immunol Inflamm 2000;8:85-91.
4. Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990;322:281-5.
5. Masuda K, Urayama A, Kogure M, Nakajima A, Nakae K, Inaba G. Double-masked trial of cyclosporin versus colchicines and long-term open study of cyclosporin in Behçet's disease. Lancet 1989;1:1093-6.
6. Ozyazgan Y, Yurdakul S, Yazici H, Tuzun B, Iscimen A, Tuzun Y, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br J Ophthalmol 1992; 76:241-3.
7. Yazici H, Ozyazgan Y. Medical management of Behçet's syndrome. Dev Ophthalmol 1999;31:118-31.
8. Kotter I, Durk H, Saal J, Fierlbeck G, Pleyer U, Zierhut M. Therapy of Behçet's disease. Ger J Ophthalmol 1996;5:92-7.
9. Gul A. Behçet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2001;19 Suppl 24:S6-12.
10. Maini SR. Infliximab treatment of rheumatoid arthritis. Rheum Dis Clin North Am 2004;30:329-47.
11. Rutgeerts P, van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126:1593-610.
12. Braun J, Sieper J. Biological therapies in the spondyloarthritides: the current state. Rheumatology (Oxford) 2004;43:1072-84.
13. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001;358:295-6.
14. Sfikakis PP. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002;61 Suppl 11:51-3.
15. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Martin-Mola E. Effect of infliximab on threatening panuveitis in Behçet's disease [letter]. Lancet 2001;358:1644.
16. Goossens PH, Verburg RJ, Breedveld FC. Remission of Behçet's syndrome with tumour necrosis factor α blocking therapy [letter]. Ann Rheum Dis 2001;60:637.
17. Triolo G, Vadala M, Accardo-Palumbo A, Ferrante A, Ciccia F, Giardina E, et al. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease. Ann Rheum Dis 2002;61:560-1.
18. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-80.
19. Direskeneli H, Kilicaslan Z, Inane M. Evaluation of patients for tuberculosis prior to treatment with anti-tumor necrosis factor-α biological agents (Consensus Meeting Report). Marmara Med J 2002;15:273-6.
20. Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Beḩet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 1999;38:728-33.
21. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 2004;140:404-6.
22. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-8.
23. Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003;87:423-31.
24. Rosenbaum JT. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behçet's disease. J Rheumatol 2004;31:1241-3.